CD19 CAR T cells, IL-13Rα2 CAR T cells, and GD2 CAR T cells engineered to secrete IL-15 have shown increased expansion and in vivo anti-tumor activity in xenograft mouse models of Burkitt lymphoma, glioma, and metastatic neuroblastoma, respectively (173–175). This evidence concerns the gene CD19 and neoplasm.